LDT

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

Retrieved on: 
Wednesday, March 20, 2024
Sepsis, Development, Lyme disease, Growth, Panel, International, Laboratory, Instrument, LDT, ASPR, Journal of Clinical Microbiology, Pharmaceutical industry

LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.

Key Points: 
  • LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.
  • The Company is currently in discussions with potential LDT partners and plans to provide early Lyme disease results to U.S. reference laboratories nationwide.
  • Engaged Dr. Robin Robinson as a strategic advisor to aid in commercialization of the T2Biothreat Panel.
  • A live and recorded webcast of the call will be available on the “Investors” section of the Company’s website at www.t2biosystems.com .

bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
Medical Devices, Surgery, FDA, Genetics, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Health, Oncology, Research, Lung cancer, Growth, CFO, Laboratory developed test, Form, Patient, Accounting, Bronchoalveolar lavage, Sale, Acquisition, Cancer, CPA, CAP, Insurance, MBA, Lung, BAL, BIAF, Bronchoscopy, LDT, Optimism, Medicare, Calendar, Marketing, CMS, Physician, Pharmaceutical industry

Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.

Key Points: 
  • Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.
  • Research and development expenses were $432,000 for the fourth quarter of 2023, compared with $429,000 for the comparable period in 2022.
  • Selling, general and administrative expenses were $2.2 million for the fourth quarter of 2023, compared with $1.2 million for the comparable period in 2022.
  • Net loss for the fourth quarter of 2023 was $2.4 million, compared with a net loss of $1.7 million for the comparable period in 2022.

Bridging Cultures: Boao Forum's Sub-Forum on Religious Harmony Sparks Global Buddhist Dialogue

Retrieved on: 
Monday, April 1, 2024
Religion, Conference, Chinese Buddhism, History, Growth, Executive Council, Kingdom, Compassion, LDT, Boao Forum for Asia, Gangaramaya Temple, Multimedia, YAN, Pure land, BFA, National Assembly, CCRP, YIN, Wisdom, Tourism

QIONGHAI, China, April 1, 2024 /PRNewswire/ -- The Sub-forum on Religious Harmony and Mutual Learning Among Civilizations took place at the Boao Forum for Asia (BFA) Annual Conference 2024 by March 29.

Key Points: 
  • QIONGHAI, China, April 1, 2024 /PRNewswire/ -- The Sub-forum on Religious Harmony and Mutual Learning Among Civilizations took place at the Boao Forum for Asia (BFA) Annual Conference 2024 by March 29.
  • The Minister of Religious Affairs of Cambodia, Chay Borin, attended the event as a special guest.
  • Let us remain steadfast in promoting harmonious development and cooperation between the East and the West as we move forward."
  • He highlighted the positive impact of Buddhist principles such as compassion, peace, the Middle Way, and consummate interfusion in addressing the shared challenges humanity faces today.

The Religious Sub-forum of BFA 2024 to Feature the First Roundtable Thought Event

Retrieved on: 
Thursday, March 28, 2024
Religion, Buddhism, Dictionary, Chinese Buddhism, Patient, Cataract, Executive Council, Wisdom, YIN, Compassion, LDT, Boao Forum for Asia, Gangaramaya Temple, Nobel, YAN, National Assembly, BFA, CCRP

QIONGHAI, China, March 28, 2024 /PRNewswire/ -- The Sub-forum on Religious Harmony and Mutual Learning Among Civilizations at the Boao Forum for Asia 2024 ("BFA 2024") is set to feature its first ever roundtable discussion on March 29th.

Key Points: 
  • QIONGHAI, China, March 28, 2024 /PRNewswire/ -- The Sub-forum on Religious Harmony and Mutual Learning Among Civilizations at the Boao Forum for Asia 2024 ("BFA 2024") is set to feature its first ever roundtable discussion on March 29th.
  • At the media conference, YIN SHUN highlighted the remarkable achievements of the past years.
  • The Buddhist Association of China has proudly hosted eight Boao Religious Sub-Forums, eight South China Sea Buddhist Roundtables, and the "Overseas Spreading and Influence of Chinese Chan Culture - Dahongshan Forum".
  • Since its inception in 2015, the religious sub-forum of BFA has completed eight sessions, attracting a distinctive lineup of esteemed guests representing many of the world's religions, Nobel laureates, nationally recognized scholars, and leading journalists.

The Religious Sub-forum of BFA 2024 to Feature the First Roundtable Thought Event

Retrieved on: 
Thursday, March 28, 2024
Patient, Executive Council, Compassion, Boao Forum for Asia, National Assembly, BFA, Buddhism, CCTV, LDT, Gangaramaya Temple, Nobel, YAN, Chinese Buddhism, Xinhua News Agency, Religion, Cataract, Dictionary, Multimedia, CCRP, YIN, Wisdom, Tourism

QIONGHAI, China, March 28, 2024 /PRNewswire/ -- The Sub-forum on Religious Harmony and Mutual Learning Among Civilizations at the Boao Forum for Asia 2024 ("BFA 2024") is set to feature its first ever roundtable discussion on March 29th.

Key Points: 
  • QIONGHAI, China, March 28, 2024 /PRNewswire/ -- The Sub-forum on Religious Harmony and Mutual Learning Among Civilizations at the Boao Forum for Asia 2024 ("BFA 2024") is set to feature its first ever roundtable discussion on March 29th.
  • The event sought to promote mutual learning between world religions and civilizations of the East and West through the "Boao Dialogue".
  • HARADA MITSUNORI commented, "I feel optimistic about future cultural exchanges between Buddhist communities in China and Japan, fostering bridges of understanding and camaraderie between our two nations."
  • The Buddhist Association of China has proudly hosted eight Boao Religious Sub-Forums, eight South China Sea Buddhist Roundtables, and the "Overseas Spreading and Influence of Chinese Chan Culture - Dahongshan Forum".

ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART

Retrieved on: 
Tuesday, February 20, 2024
Marie Cassidy, Prophase, Barrett's esophagus, Patent, Gastroenterology, LDT, Risk, Cancer, GI, Mayo Clinic, The Wall Street Journal, Clinical professor, Patient, Carcinogenesis, Clinical trial, Genomics, Esophageal cancer, Plague

This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.

Key Points: 
  • This breakthrough test, in development for nearly five years, is nearing completion of clinical studies.
  • If the clinical trial results are successful, the Company will be aiming for commercial launch during 2024.
  • Recently, an additional 139 specimens were analyzed in collaboration with The Mayo Clinic, for the purposes of assessing the test's precision and reliability in identifying esophageal adenocarcinoma risk.
  • - The test has demonstrated molecular precision in excess of 99%1, which is a remarkably precise accomplishment in cancerous tissue analysis.

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, PSNL, Neoplasm, Immunotherapy, Investment, DX, Lung, LDT, NeXT, Medicare, Tempus, MRD, Genomics, Partnership, Video game

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.
  • “Our efforts in 2024 continue to be focused on executing our Win-in-MRD strategy for NeXT Personal.
  • The conference call can be accessed live by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers.
  • A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

Retrieved on: 
Thursday, February 22, 2024
Software, Professional Services, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Health Technology, Data Analytics, Biotechnology, FDA, Health, ASPS, Acquisition, Joint venture, PMA, Forecasting, Marketing, Growth, CRC, LDT, GAAP, Webcast, Net, Helmy Eltoukhy, Research, Depreciation, Shield, Pharmaceutical industry

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023.
  • Development services and other revenue was $12.9 million for the fourth quarter of 2023, compared to $13.1 million for the corresponding prior year period.
  • Precision oncology gross margin was 60% in the fourth quarter of 2023, as compared to 62% in the prior year period.
  • Guardant Health will host a conference call to discuss the fourth quarter and full year 2023 financial results after market close on Thursday, February 22, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

Lab Community "Extremely Concerned" About Patient Access to Testing If FDA Regulates Lab-Developed Tests

Retrieved on: 
Tuesday, March 5, 2024
Marie Cassidy, Doctor of Philosophy, ARUP, MD, Synovial joint, Physician, FDA, ARUP Laboratories, Culture, 2005 in television, Manuscript, LDT, Feedback, Safety, Health, MedRxiv, Patient, Congress, Laboratory, Public, Medical device

"If labs cannot afford to comply with the proposed regulations, they will have to discontinue essential tests, and that harms patients."

Key Points: 
  • "If labs cannot afford to comply with the proposed regulations, they will have to discontinue essential tests, and that harms patients."
  • To better understand how clinical laboratorians perceive the proposed rule, ARUP Laboratories conducted a survey of the clinical laboratory community.
  • Most respondents identified themselves as lab managers, lab supervisors, lab directors, lab employees, medical directors, pathologists, physicians, clinicians, or PhD scientists.
  • Over a hundred thousand clinical laboratorians dedicate their professional lives to ensuring high-quality testing and patient care every day in the U.S.

CND Life Sciences Partners with Visiopharm on Novel AI-Tool to Detect and Quantify Pathological Alpha-Synuclein in Cutaneous Nerves

Retrieved on: 
Tuesday, March 5, 2024
Parkinson's disease, Marie Cassidy, Algorithm, Ariz, CND, MD, Pathology, Drug development, Alpha-synuclein, Neurology, LDT, Disease, Patient, Clinical trial, Sympathetic nervous system, Synucleinopathy, Diagnosis, Machine learning, Three-body problem, Deep learning, Lewy body, Partnership, Medical imaging

SCOTTSDALE, Ariz.., March 5, 2024 /PRNewswire/ -- CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today will unveil its NerValence pathology detection system at the AD/PD 2024 conference in Lisbon, Portugal. NerValence, developed through a strategic collaboration with precision pathology company Visiopharm, significantly enhances CND's biomarker testing services for clinical trials targeting the alpha-synuclein protein in patients with suspected Parkinson's disease, dementia with Lewy bodies, and related disorders.

Key Points: 
  • NerValence aids in the identification, tracking, and measuring the volume of alpha-synuclein in cutaneous nerves.
  • NerValence features machine learning algorithms that recognize and differentiate microscopic structures, nerves, and important disease markers that can be found in cutaneous tissue.
  • "Utilizing our novel deep learning technology to power this crucial advancement in neurodegenerative diseases represents a significant leap forward in analyzing peripheral nerves," said Michael Grunkin , Visiopharm Chief Executive Officer.
  • "Collaborating with CND Life Sciences on its deployment of NerValence will continue to be a major priority as we advance AI-driven precision pathology to enhance biopharmaceutical drug development."